Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis

Inclusion Criteria: * Subjects seeking medical treatment for symptoms consistent with IC that have been ongoing for \> 9 months or seeking medical treatment for a previous documented diagnosis of IC * Subjects who are not surgically sterile or postmenopausal (amenorrheic \> 12 months) must agree and commit to the use of a medically acceptable, highly-effective (i.e. double-barrier or IUD), non-hormonal form of birth control during the study and for 30 days after the last dose of test Exclusion Criteria: * Use of herbal supplements (except for a daily multivitamin/mineral supplement not containing herbal components) * History of cancer (other than resected cutaneous basal or squamous cell carcinoma or in situ cervical cancer) with less than 5 years documentation of a disease-free state * Vaginitis or vaginal infection within 1 month before randomization